<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01573507</url>
  </required_header>
  <id_info>
    <org_study_id>237/10</org_study_id>
    <nct_id>NCT01573507</nct_id>
  </id_info>
  <brief_title>Lactate Therapy After Traumatic Brain Injury</brief_title>
  <acronym>LS_TCC</acronym>
  <official_title>Neuroprotective Role of Lactate Therapy in Humans With Traumatic Brain Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Vaudois</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Swiss National Science Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>European Society of Intensive Care Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire Vaudois</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: Although glucose is essential to cerebral function, abundant experimental and&#xD;
      clinical evidence demonstrates that endogenously released lactate, rather than glucose, is&#xD;
      the preferential energy substrate for the brain in conditions of stress and acute injury. In&#xD;
      patients with severe Traumatic Brain Injury (TBI) and aneurysmal subarachnoid hemorrhage&#xD;
      (SAH) monitored with cerebral microdialysis and brain tissue oxygen (PbtO2), our preliminary&#xD;
      data show that increased brain extracellular lactate is frequently observed. Our findings&#xD;
      indicate that elevated brain lactate more often occurs in the absence of brain&#xD;
      hypoxia/ischemia and is mainly the consequence of increased cerebral glycolysis, i.e. it&#xD;
      occurs in association with high extracellular pyruvate. These data suggest that the primary&#xD;
      source of elevated lactate is activated glycolysis and strongly support the concept that&#xD;
      endogenously released lactate can be utilized by the injured human brain as energy substrate.&#xD;
      They prompt further investigation to examine whether exogenous lactate supplementation can be&#xD;
      a valuable neuroprotective strategy after TBI or SAH. Indeed, in animal models of brain&#xD;
      injury, administration of exogenous lactate improves neuronal and cognitive recovery.&#xD;
&#xD;
      Hypothesis: The investigators test the hypothesis that lactate therapy, administered during&#xD;
      the acute phase of TBI or SAH, might exercise neuroprotective actions by restoring brain&#xD;
      energetics and improving brain tissue PO2 and cerebral blood flow (CBF).&#xD;
&#xD;
      Aim of the study: The aim of this single-center study is to examine the effect of sodium&#xD;
      lactate infusion on cerebral extracellular metabolites, brain tissue PO2 and cerebral blood&#xD;
      flow, measured with CT perfusion and transcranial doppler (TCD).&#xD;
&#xD;
      Design: Prospective phase II interventional study examining the effect of a continuous 3-6&#xD;
      hours infusion of sodium lactate (20-40 µmol/kg/min), administered within 48 hours from TBI&#xD;
      or SAH, on cerebral extracellular glucose, pyruvate, glutamate, glycerol, PbtO2 and CBF.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study: Prospective, single-centre phase II interventional study. The study will take place at&#xD;
      the Department of Intensive Care Medicine, Lausanne University Medical Center (Centre&#xD;
      Hospitalier Universitaire Vaudois, CHUV), Lausanne, Switzerland.&#xD;
&#xD;
      Patient population:&#xD;
&#xD;
      Patients will be monitored with an intra-parenchymal monitoring system, consisting of ICP&#xD;
      (Codman®, Integra Neurosciences), PbtO2 (Licox®, Integra Neurosciences) and cerebral&#xD;
      microdialysis (CMA Microdialysis®) catheters, based on the protocol for management of TBI&#xD;
      presently in use at our center.&#xD;
&#xD;
      Each patient will receive a continuous infusion of sodium lactate (composition: lactate 1'000&#xD;
      mmol/L, Na 1'000 mmol/L: concentration 20-40 µmol/kg/min) for 3-6 hours. Sodium lactate will&#xD;
      be prepared locally by the Pharmacie Centrale, CHUV, Lausanne.&#xD;
&#xD;
      Each patient will serve as his/her internal control, and the effect of sodium lactate on all&#xD;
      brain physiological variables measured will be anayzed before, during and at the end of&#xD;
      sodium lactate infusion.&#xD;
&#xD;
      The main parameters of efficacy are increases of MD glucose, MD pyruvate, PbtO2, and CBF,&#xD;
      during sodium lactate perfusion.&#xD;
&#xD;
      For both MD glucose and MD pyruvate, we fixed as the minimal detectable effect of sodium&#xD;
      lactate infusion a 30% increase of glucose and pyruvate at the end of the study. To obtain a&#xD;
      power of 0.8 with an alpha of 0.05, the number of patients required to complete the study is&#xD;
      33. We therefore plan to include 35 patients.&#xD;
&#xD;
      Statistical analysis: At each time-point (baseline, during perfusion, end of sodium lactate&#xD;
      infusion), differences of mean MD glucose, lactate, pyruvate, PbtO2, CBF, Mean transit time,&#xD;
      ICP, CPP will be analyzed. We will also examine the percentage time spent with abnormal&#xD;
      values (MD glucose &lt; 1 mmol/L, PbtO2 &lt; 20 mm Hg, ICP &gt; 20 mm Hg). Differences will be&#xD;
      compared using ANOVA for repeated measures.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2012</start_date>
  <completion_date type="Actual">December 18, 2017</completion_date>
  <primary_completion_date type="Actual">December 18, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Hypertonic lactate</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Increase from baseline in brain extracellular lactate, pyruvate and glucose</measure>
    <time_frame>6 hours</time_frame>
    <description>Increase from baseline in brain extracellular lactate, pyruvate and glucose measured with intra-parenchymal cerebral microdialysis catheter</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Increase from baseline in brain tissue PO2</measure>
    <time_frame>6 hours</time_frame>
    <description>Brain tissue PO2 will be measured with intra-parenchymal probes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Increase from baseline in cerebral perfusion pressure</measure>
    <time_frame>6 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease from baseline in intracranial pressure</measure>
    <time_frame>6 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma sodium</measure>
    <time_frame>6 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma osmolality</measure>
    <time_frame>6 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mean CBF, measured by transcranial doppler</measure>
    <time_frame>6 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Traumatic Brain Injury</condition>
  <condition>Subarachnoid Hemorrhage</condition>
  <arm_group>
    <arm_group_label>sodium lactate infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Continuous i.v. infusion of Sodium Lactate (2'400 mOsmol/L) over 3 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>sodium lactate infusion</intervention_name>
    <description>3-6 hours continuous infusion of sodium lactate (20-40 mcg/kg/min)</description>
    <arm_group_label>sodium lactate infusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients admitted to our intensive care unit (ICU) after severe TBI or poor-grade&#xD;
             aneurysmal subarachnoid hemorrhage (SAH), defined by a post-resuscitation Glasgow Coma&#xD;
             Scale (GCS) &lt; 9&#xD;
&#xD;
          -  Age 18-75 years&#xD;
&#xD;
          -  Abnormal head CT-scan (Marshall grade ≥ 2 or Fisher &gt;2)&#xD;
&#xD;
          -  Intracranial pressure (ICP), PbtO2 and cerebral MD monitoring as part of standard care&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Penetrating TBI&#xD;
&#xD;
          -  non aneurysmal SAH&#xD;
&#xD;
          -  Age &lt; 18 or &gt; 75 years,&#xD;
&#xD;
          -  More than 1 extra-cranial injury with sustained hemodynamic instability and sustained&#xD;
             blood lactate elevation &gt; 4 mmol/L&#xD;
&#xD;
          -  Cognitive handicap due to previous neurological or neurosurgical history&#xD;
&#xD;
          -  Non-survivable injury, brain death or expected death within 48 hours&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mauro Oddo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHUV, Lausanne University Hospital, Switzerland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHUV, Lausanne University Hospital</name>
      <address>
        <city>Lausanne</city>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 1, 2012</study_first_submitted>
  <study_first_submitted_qc>April 6, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2012</study_first_posted>
  <last_update_submitted>September 8, 2021</last_update_submitted>
  <last_update_submitted_qc>September 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre Hospitalier Universitaire Vaudois</investigator_affiliation>
    <investigator_full_name>Mauro ODDO</investigator_full_name>
    <investigator_title>médecin adjoint, PD-MER I</investigator_title>
  </responsible_party>
  <keyword>traumatic brain injury</keyword>
  <keyword>lactate</keyword>
  <keyword>brain metabolism</keyword>
  <keyword>cerebral microdialysis</keyword>
  <keyword>subarachnoid hemorrhage</keyword>
  <keyword>transcranial doppler</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
    <mesh_term>Subarachnoid Hemorrhage</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

